TY - JOUR
T1 - Efficacy of a Telemonitoring System as a Complementary Strategy in the Treatment of Patients With Heart Failure Randomized Clinical Trial
AU - Achury-Saldaña, Diana M.
AU - Gonzalez, Rafael A.
AU - Garcia, Angel
AU - Mariño, Alejandro
AU - Bohorquez, Wilson R.
N1 - Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc.
PY - 2024/4/24
Y1 - 2024/4/24
N2 - Episodes of decompensation are the main cause of hospital admissions in patients with heart failure. For this reason, the use of mobile apps emerges as an excellent strategy to improve coverage, real-time monitoring, and timeliness of care. ControlVit is an electronic application for early detection of complications studied within the context of a tertiary university hospital. Patients were randomized to the use of ControlVit versus placebo, during a 6-month follow-up. The primary outcome was the difference in numbers of readmissions and deaths for heart failure between both groups. One hundred forty patients were included (intervention = 71, placebo = 69), with an average age of 66 years old; 71% were men. The main etiology of heart failure was ischemic (60%), whereas the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). The primary outcome occurred more frequently in the control group: readmission due to decompensation for heart failure (control group n = 14 vs intervention group n = 3; P = .0081), and death (control group n = 11 vs intervention group n = 3; P = .024). In heart failure patients, ControlVit is a useful and supplementary tool, which reduces hospital admissions due to episodes of decompensation.
AB - Episodes of decompensation are the main cause of hospital admissions in patients with heart failure. For this reason, the use of mobile apps emerges as an excellent strategy to improve coverage, real-time monitoring, and timeliness of care. ControlVit is an electronic application for early detection of complications studied within the context of a tertiary university hospital. Patients were randomized to the use of ControlVit versus placebo, during a 6-month follow-up. The primary outcome was the difference in numbers of readmissions and deaths for heart failure between both groups. One hundred forty patients were included (intervention = 71, placebo = 69), with an average age of 66 years old; 71% were men. The main etiology of heart failure was ischemic (60%), whereas the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). The primary outcome occurred more frequently in the control group: readmission due to decompensation for heart failure (control group n = 14 vs intervention group n = 3; P = .0081), and death (control group n = 11 vs intervention group n = 3; P = .024). In heart failure patients, ControlVit is a useful and supplementary tool, which reduces hospital admissions due to episodes of decompensation.
KW - Heart failure
KW - Hospitalization
KW - Mobile application
KW - Randomized clinical trial
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85197632363&partnerID=8YFLogxK
U2 - 10.1097/CIN.0000000000001115
DO - 10.1097/CIN.0000000000001115
M3 - Article
AN - SCOPUS:85197632363
SN - 1538-2931
VL - 42
SP - 522
EP - 529
JO - Computers, informatics, nursing : CIN
JF - Computers, informatics, nursing : CIN
IS - 7
ER -